GSK3B and brain neoplasm: To preliminarily test this supposition, we employed the irreversible Gsk3β inhibitor tideglusib, a drug in several clinical trials for its effects on stem cells and that has shown antiproliferative and antitumorigenic effects on brain tumors (27–29).